59 terminated. 59 Phase 3, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 59 | Terminated 59 |
| Phase 2 | 11 | Terminated 11 |
Follow Head and Neck Neoplasms: new trials by email Literature Review of Head and Neck Neoplasms trials Research Report on Head and Neck Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy - Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 3 | Terminated | PDS Biotechnology Corp. | 12 | 2025-05-30 | 2026-09-02 |
| Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer Xevinapant, Placebo, cetuximab - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Terminated | Groupe Oncologie Radiotherapie Tete et Cou | 19 | 2023-12-12 | 2025-05-09 |
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) Xevinapant, IMRT, Placebo - Head and Neck Cancer | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 166 | 2022-10-06 | 2026-02-19 |
| BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) Bempegaldesleukin, Pembrolizumab - Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | Phase 2 / Phase 3 | Terminated | Nektar Therapeutics | 1 | 2022-03-09 | 2023-01-12 |
| Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules Radiofrequency ablation, Radioactive iodine - Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function | Phase 3 | Terminated | Rijnstate Hospital | 40 | 2021-11-17 | 2025-07-17 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). Pembrolizumab, Lenvatinib, Cisplatin - Metastatic Esophageal Squamous Cell Carcinoma | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 863 | 2021-07-28 | 2026-08-21 |
| Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet - Chemoradiotherapy-Induced Severe Oral Mucositis | Phase 2 / Phase 3 | Terminated | Monopar Therapeutics | 190 | 2021-02-11 | 2023-05-31 |
| Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Carboplatin, Cisplatin, Gemcitabine - Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 15 | 2020-12-09 | 2025-10-03 |
| Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Feladilimab, Pembrolizumab, Placebo - Neoplasms, Head and Neck | Phase 3 | Terminated | GlaxoSmithKline | 117 | 2020-08-12 | 2024-10-09 |
| A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) Xevinapant (Debio 1143), Cisplatin, Intensity Modulation Radiation Therapy (IMRT) - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 730 | 2020-08-07 | 2025-10-08 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Pralsetinib, Carboplatin, Cisplatin - RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm | Phase 3 | Terminated | Hoffmann-La Roche | 223 | 2020-07-24 | 2026-03-05 |
| Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery Ketamine, Placebo Ketamine, Lidocaine - Postoperative Pain Control, Opioid Consumption | Phase 3 | Terminated | Case Comprehensive Cancer Center | 30 | 2020-01-17 | 2024-11-12 |
| Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma feladilimab, Pembrolizumab, Placebo - Neoplasms, Head and Neck | Phase 3 | Terminated | GlaxoSmithKline | 315 | 2019-11-21 | 2024-07-10 |
| Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery Gabapentin, Placebo - Concentrate - Cancer of Head and Neck, Narcotic Use | Phase 3 | Terminated | University of California, Davis | 8 | 2018-12-01 | 2021-07-09 |
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck Standard care of parenteral nutrition, Parenteral over night nutrition, Cetuximab - Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV | Phase 3 | Terminated | Arbeitsgemeinschaft medikamentoese Tumortherapie | 8 | 2017-02-03 | 2020-05-01 |
| Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) Avelumab, Chemoradiation - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Terminated | Pfizer | 697 | 2016-11-28 | 2021-09-22 |
| Comparing Palliative Radiotherapy With or Without Carboplatin irradiation + carboplatin, irradiation + placebo - Lung Cancer, Head and Neck Cancer | Phase 3 | Terminated | Institut Cancerologie de l'Ouest | 26 | 2015-08-17 | 2026-06-09 |
| A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA MEP - Nasopharyngeal Carcinoma | Phase 3 | Terminated | National Health Research Institutes, Taiwan | 10 | 2014-12-14 | 2025-08-19 |
| LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy Placebo, Afatinib - Head and Neck Neoplasms | Phase 3 | Terminated | Boehringer Ingelheim | 36 | 2014-07-17 | 2019-03-01 |
| Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma Etoposide phosphate, Carboplatin, Ifosfamide - Recurrent Nasopharynx Carcinoma | Phase 3 | Terminated | University of Florida | 1 | 2014-06-01 | 2019-06-24 |
Showing 20 of 59. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (16) · Carcinoma, Squamous Cell (9) · Esophageal Neoplasms (8) · Lung Neoplasms (6) · Neoplasms (6) · Esophageal Squamous Cell Carcinoma (4) · Laryngeal Diseases (4) · Oropharyngeal Neoplasms (4) · Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (3) · Mouth Neoplasms (3) · Nasopharyngeal Carcinoma (3) · Neoplasms, Squamous Cell (3) · Stomatitis (3)
Neoplasms by Site (58) · Neoplasms (53) · Neoplasms by Histologic Type (32) · Neoplasms, Glandular and Epithelial (32) · Carcinoma (28) · Carcinoma, Squamous Cell (17) · Digestive System Diseases (14) · Gastrointestinal Diseases (14) · Otorhinolaryngologic Diseases (13) · Stomatognathic Diseases (13) · Digestive System Neoplasms (12) · Esophageal Diseases (11) · Gastrointestinal Neoplasms (11) · Neoplasms, Squamous Cell (11)
Cisplatin (15) · Fluorouracil (8) · Radiotherapy (8) · pembrolizumab (6) · Carboplatin (5) · Paclitaxel (5) · Cetuximab (3) · Docetaxel (3) · Afatinib (2) · Bleomycin (2) · Celecoxib (2) · Chemoradiotherapy (2) · Erlotinib Hydrochloride (2) · Esophagectomy (2) · Gabapentin (2)
Boehringer Ingelheim (3) · National Health Research Institutes, Taiwan (3) · EMD Serono Research & Development Institute, Inc. (2) · GlaxoSmithKline (2) · Groupe Oncologie Radiotherapie Tete et Cou (2) · Hoffmann-La Roche (2) · Inovio Pharmaceuticals (2) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Radiation Therapy Oncology Group (2) · SWOG Cancer Research Network (2) · Washington University School of Medicine (2) · AIO-Studien-gGmbH (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Asan Medical Center (1)
United States (34) · France (15) · Germany (13) · Spain (12) · United Kingdom (12) · Italy (11) · Canada (10) · Japan (9) · Poland (9) · South Korea (9) · Argentina (8) · China (8) · Israel (8) · Russia (8) · Taiwan (8)
Paul Goldfarb, MD (2) · Anna Sureda (1) · Ara Vaporciyan, MD, BS (1) · Arnaud Bewley, MD (1) · Athanassios Argiris (1) · Bonnie C Abbruzzese, MS RD (1) · Brigette B Ma (1) · Chia-Jui Yen Yen, MD. PhD (1) · Ching-Yun Hsieh, MD (1) · David I. Rosenthal, MD (1) · David J. Adelstein, MD (1)
PMID 16467544, PMID 16782926, PMID 16794899, PMID 19897418, PMID 21918956, PMID 22261362, PMID 23460714, PMID 24051744, PMID 25057165, PMID 25432788, PMID 25670018, PMID 27389475, PMID 28688693, PMID 30291834, PMID 31194247, PMID 31959339, PMID 32044419, PMID 33794205, PMID 35172587, PMID 37816266, PMID 38197296, PMID 38695479, PMID 40902136
2019 (3), 2023 (2), 2005 (1), 2016 (1), K23CA115908 (1), U10CA021115 (1), U10CA032102 (1), U10CA037429 (1), U10CA180868 (1)